Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Titel:
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Auteur:
Richardson, Paul G Oriol, Albert Beksac, Meral Liberati, Anna Marina Galli, Monica Schjesvold, Fredrik Lindsay, Jindriska Weisel, Katja White, Darrell Facon, Thierry San Miguel, Jesus Sunami, Kazutaka O'Gorman, Peter Sonneveld, Pieter Robak, Pawel Semochkin, Sergey Schey, Steve Yu, Xin Doerr, Thomas Bensmaine, Amine Biyukov, Tsvetan Peluso, Teresa Zaki, Mohamed Anderson, Kenneth Dimopoulos, Meletios